Breaking Finance News

Stemline Therapeutics Inc (NASDAQ:STML) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded Stemline Therapeutics Inc (NASDAQ:STML) to Hold in a report released on 02/09/2017.

Previously on 2/06/2017, Wedbush reported on Stemline Therapeutics Inc (NASDAQ:STML) reduced the target price from $19.00 to $11.00. At the time, this indicated a possible upside of 0.68%.

Yesterday Stemline Therapeutics Inc (NASDAQ:STML) traded -1.44% lower at $6.65. The company’s 50-day moving average is $10.38 and its 200-day moving average is $10.48. The last closing price is down -34.61% from the 200-day moving average, compared to the S&P 500 which has increased 0.06% over the same time period. 395,024 shares of the stock traded hands, up from an average trading volume of 331,798

See Chart Below

Stemline Therapeutics Inc (NASDAQ:STML)

Stemline Therapeutics Inc has a 52 week low of $3.88 and a 52 week high of $14.60 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 5 brokers have issued a report on the company. The average stock price target is $31.20 with 3 brokers rating the stock a strong buy, 3 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Stemline Therapeutics Inc (NASDAQ:STML)

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.